Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats chemotherapy‑induced nausea and vomiting and postoperative nausea and vomiting in patients undergoing cancer therapy or surgery, helping to reduce the frequency and severity of these symptoms.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kytril (granisetron) is used to control nausea and vomiting mediated by the serotonergic pathway.

Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed nausea and vomiting in patients receiving cytotoxic chemotherapy. Postoperative nausea and vomiting: prevents and treats nausea and vomiting after surgical procedures. Radiation‑therapy‑induced nausea and vomiting: helps control nausea associated with radiation treatment.

Granisetron may cause adverse reactions. Monitoring and reporting are recommended.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhea - Abdominal pain

Serious or Rare Side Effects: - Cardiac arrhythmia or QT interval prolongation - Severe allergic reaction (anaphylaxis) - Serotonin syndrome - Severe hypotension

Before prescribing Kytril, consider the following precautions.

Assess cardiac history: monitor QT interval in patients with known cardiac conduction abnormalities. Avoid concomitant use with other QT‑prolonging agents: evaluate risk of additive effects. Renal impairment: use with caution in severe renal dysfunction. Hepatic impairment: adjust use in moderate liver disease. Pregnancy and lactation: weigh potential benefits against limited safety data. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Kytril can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: concurrent use may increase risk of cardiac arrhythmia. - Cisapride: combined use can cause severe QT prolongation. - Antiarrhythmic drugs (e.g., amiodarone, quinidine): may potentiate QT effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise granisetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Opioids: additive antiemetic effect may increase sedation, requiring monitoring.